Sun protection devices and methods

Abstract

A product for treating a subject comprises a light conversion medium that receives broad spectrum ambient light and emits light of one or more peak wavelengths or wavelength ranges ([lambda] 1, [lambda] 2, [lambda] 3) having an intensity greater than a corresponding intensity in the received broad spectrum ambient light. The product is specifically designed for UV protection and can be used for treating and caring for a plurality of different types of skin, and the selected wavelength has a treatment or enhancement effect so as to influence the biological progress occurring inside the skin or directly influencing the skin. These products may not only be present as separate treatments, but also be used in combination with existing treatments to achieve improved or differentiated effects.

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480029880.7 (22) Application Date 2024.03.15 (30) Priority Data 63 / 490,574 2023.03.16 US (85) PCT International Application Entering National Phase Date 2025.11.03 (86) PCT International Application Application Data PCT / US2024 / 020259 2024.03.15 (87) PCT International Application Publication Data WO2024 / 192400 EN 2024.09.19 (71) Applicant: Zachary Bolduk Address: 158-1 North End Avenue, Salisbury, Massachusetts, USA Applicant: Roy Alan Bolduk Douglas Price Hemelep (72) Inventors: Zachary Bolduk Roy Alan Bolduk Douglas Price Hemelep (74) Patent Agency: Shenzhen Shangye Intellectual Property Agency (General Partnership) 44503 Patent Attorney: Wen Rong (51) Int.Cl. A61K 8 / 25 (2006.01) A61K 8 / 27 (2006.01) A61K 8 / 29 (2006.01) A61Q 17 / 04 (2006.01) A61K 8 / 06 (2006.01) B82Y 20 / 00 (2006.01) (54) Invention Title: Sunscreen Device and Method (57) Abstract: A product for treating a subject, comprising a light conversion medium that receives broad-spectrum ambient light and emits light of one or more peak wavelengths or wavelength ranges (λ1, λ2, λ3) with an intensity greater than the corresponding intensity in the received broad-spectrum ambient light. The product is specifically designed for ultraviolet protection and can be used for various types of skin treatments, with selected wavelengths having therapeutic or enhancing effects to influence biological processes occurring within the skin or directly affecting the skin. These products can be used either as standalone treatments or in combination with existing treatments to achieve improved or differentiated effects.Claims (2 pages), Description (6 pages), Drawings (2 pages), CN 121463938 A 2026.02.03 CN 1 21 46 39 38 A 1. A composition comprising: a. a plurality of quantum dots, each quantum dot encapsulated in an encapsulation compound capable of transmitting a first wavelength spectrum, wherein the quantum dots are configured to absorb ambient light in the first wavelength range and emit light in a second wavelength range, the second wavelength range being encompassed by the first wavelength range, wherein a first portion of the plurality of quantum dots is configured to emit light in the second wavelength range, the light in the second wavelength range being different from the light emitted by a second portion of the plurality of quantum dots. 2. A composition for protecting against ultraviolet radiation damage, defects, or unsightly symptoms, comprising a light conversion medium that receives a broad spectrum of ambient light containing ultraviolet radiation and emits light with one or more peak wavelengths or wavelength ranges (λ1, λ2, λ3) at an intensity greater than the corresponding intensity in the received broad spectrum of ambient light. 3. The composition according to claim 2, wherein the one or more peak wavelengths or wavelength ranges λ1, λ2, λ3 are from about 200 nm to about 3000 nm, optionally in the ultraviolet band, optionally from about 200 nm to about 400 nm, optionally in the long-wave ultraviolet band, optionally from about 310 nm to about 360 nm, optionally in the visible light band, optionally from about 400 nm to about 600 nm, optionally in the infrared band, optionally from about 600 nm to about 3000 nm, optionally in the near-infrared band, optionally from about 810 nm to about 850 nm. 4. The composition according to claim 2, wherein the light conversion medium comprises a carrier medium and a light conversion element. 5. The composition according to claim 4, wherein the particulate light conversion medium is supported by a transparent carrier or a supporting medium, optionally the supporting medium being transparent, translucent, or opaque. 6. The composition of claim 5, wherein the particulate light conversion medium is suspended in the carrier medium or molecularly bonded to the carrier medium, thereby forming a novel hybrid material. 7. The composition of claim 5, wherein the carrier medium is a solid material, such as a plastic material, a polymer material, or an organic material, optionally the solid carrier medium being rigid, semi-rigid, or flexible. 8. The composition of claim 5, wherein the carrier medium is a fluid material, such as a gel, cream, or liquid. 9. The composition of claim 8, wherein the fluid material comprises one or more compounds, the compounds comprising one or more collagen-dissolving enzymes.10. The composition of claim 9, wherein the formulation comprises 0.005-5% silicon quantum dots; 5-15% zinc oxide; and 10-15% titanium dioxide. The ranges may be expressed as mass / mass percentage (%m / m), weight / weight percentage (%w / w), weight / volume percentage (%w / v), mass / volume percentage (%m / v), or volume / volume percentage (%v / v). 11. The composition of claim 8, wherein the product is a composition that can be directly applied to a subject, for example, applied to the skin, for example as a topical cream, gel, or ointment, (i) a biocompatible material, or modified to be biocompatible, or (ii) encapsulated to prevent direct contact with the subject, optionally, the encapsulated fluid-carrying medium having the form of a gel, cream, or ointment for topical application to human skin. 12. A method for treating skin diseases, defects, or unsightly symptoms, the method comprising: applying a composition comprising at least a plurality of quantum dots, each quantum dot encapsulated in an encapsulating compound that transmits a first wavelength spectrum, wherein the quantum dots are configured to absorb ambient light in the first wavelength range and emit light in a second wavelength range, the second wavelength range being encompassed by the first wavelength range, wherein a first portion of the plurality of quantum dots is configured to emit light in the second wavelength range, the light in the second wavelength range being different from the light emitted by a second portion of the plurality of quantum dots. 13. The method of claim 12, wherein the skin disease, defect, or unsightly symptom is one of scar tissue, existing ultraviolet damage, wrinkles, discoloration, erythema, solar erythema, and inflammation. 14. The method of claim 12, wherein the applied composition is in the form of a gel, cream, or ointment. 15. The product of claim 2, wherein the product can be combined or mixed with current therapeutic ingredients, formulations, or methods to enhance or differentiate from existing products. 16. The product of claim 2, wherein the average diameter of the main component of the particulate matter of the light conversion medium is about 0.1 nm to about 1000 nm; optionally, about 0.1 nm to about 100 nm; optionally, about 0.1 nm to about 10 nm; optionally, about 1 nm to about 10 nm; optionally, about 10 nm to about 100 nm. 17. The product of claim 2, wherein the light conversion medium comprises nanocrystals or nanoparticle semiconductors. 18. The product of claim 15, wherein the light conversion medium comprises quantum dots or Q-dots (QDs).19. The product according to claim 16, wherein the light conversion medium comprises single-shell QDs, multi-shell QDs, heavy metal QDs and / or non-heavy metal QDs. 20. The product according to claim 17, wherein the light conversion medium comprises silicon quantum dots bonded to the molecules of the transparent medium. Claims 2 / 2 pages 3 CN 121463938 A Sunscreen Device and Method Technical Field

[0001] This invention relates to a device, system, and method for providing ultraviolet light therapy protection to subjects in need. Background Art

[0002] Sunscreen, also known as ultraviolet (UV) protection, involves using chemical substances and physical particles to absorb or reflect ultraviolet radiation. For example, existing sunscreen formulations sometimes use physical UV absorbers such as zinc oxide in skin creams to provide UV protection to the human body.

[0003] Currently, commercially available UV protection technologies typically contain one or more known UV absorbers, such as zinc oxide, to absorb or reflect incident ultraviolet radiation and protect subjects from UV radiation by a certain protection factor. For example, many existing commercial products use different organic molecules, either alone or in combination, that contain chemical bonds capable of absorbing ultraviolet radiation. While these methods are effective, they are subject to rigorous scrutiny due to their potential health and environmental hazards. In considering ultraviolet protection, the industry has established different bands, with two main bands being long-wave ultraviolet (UVA) and medium-wave ultraviolet (UVB). UVB ranges from 280 nm to 315 nm, while UVA ranges from 315 nm to 400 nm. Existing commercial ultraviolet protection products can protect against UVB alone or simultaneously against both UVB and UVA.

[0004] The inventors have developed new compositions, platforms, systems, and methods for improving ultraviolet protection for mammals, including humans. Summary of the Invention

[0005] In one or more embodiments, the present invention relates to one or more light conversion devices that receive and absorb the ultraviolet spectrum (whether sunlight or an artificial light source) and emit light with one or more peak wavelengths or wavelength ranges. In one particular embodiment, the intensity of the emitted wavelength or wavelength range is greater than the intensity of the corresponding wavelength in the received broad-spectrum ambient light. However, it is important that these light conversion devices convert UVA and UVB light into wavelengths that are less harmful to individual health.

[0006] In one or more further specific embodiments, one or more phototherapy platforms are configured to provide phototherapy to a subject. The phototherapy platform is configured with at least one luminescent compound configured to receive a broad spectrum of light, including the ultraviolet spectrum, and to emit at least a portion of the total wavelength of the received broad spectrum, wherein the intensity of the emitted wavelength portion is greater than the intensity of the corresponding portion of the received broad spectrum of light.

[0007] In another embodiment, the luminescent compound is configured to emit light absorbed in a first wavelength range and light not in the first wavelength range in a second wavelength range.

[0008] In another embodiment, the luminescent compound comprises one or more quantum dots tuned to emit a specific emission spectrum that matches at least the absorption spectrum of cytochrome C oxidase or other transmembrane protein complexes involved in cellular respiration, repair, or regulation.

[0009] In a particular embodiment, the above disclosure relates to phototherapy or photoprotection products, including compositions incorporated into topical creams, gels, and ointments. Such products for UV protection and photoprotection can be used in one or more methods of skin treatment, including but not limited to UV damage, DNA damage, wrinkle elimination or reduction. Specification 1 / 6 pages 4 CN 121463938 A Brief Description of the Drawings

[0010] The subject matter disclosed herein is illustrated in part by way of example and is intended to be illustrative rather than limiting. In the drawings, the same reference numerals are used to denote the same or corresponding parts, and wherein: Figure 1 illustrates a sun protection phototherapy according to the subject matter described herein.

[0011] Figure 2 illustrates sun protection phototherapy according to the subject matter described herein.

[0012] Figure 3 provides a graph detailing the performance of the composition relative to other compositions.

[0013] Specific Embodiments In the overview and introduction, various embodiments of the compositions and methods described herein are directed to ultraviolet protection and photoprotection platforms. In specific embodiments of the described ultraviolet protection and photoprotection platform, the platform is implemented in the form of one or more compositions designed to generate light within a specified wavelength range upon exposure to ultraviolet radiation in ambient light. In further specific embodiments, the ultraviolet protection and photoprotection platform comprises one or more films, filters, gels, creams, and ointments containing luminescent compounds that may be used as part of a complete skin treatment or as any ultraviolet protection measure applied to the skin or other biological surfaces of a subject (e.g., a human).

[0014] In further specific embodiments, the ultraviolet protection and photoprotection platform comprises one or more encapsulated quantum dot formulations configured to emit light in a wavelength range suitable for phototherapy.

[0015] In further specific embodiments, a method is provided to provide a combination of photoprotection and phototherapy to a subject using one or more encapsulated quantum dots. In specific embodiments, the ultraviolet protection and photoprotection platform and its usage methods provided herein are intended to provide phototherapy for treatment or other skin treatments. For example, the wavelengths emitted by the ultraviolet protection and photoprotection platform can be used to treat ultraviolet damage, wrinkles, and scars on an individual's skin.

[0016] In one or more embodiments, the foregoing provides one or more methods for providing a UV protection and photoprotection platform to a person requiring treatment, wherein the method includes using a fluid, gel, or cream UV protection and photoprotection platform as UV protection and treatment for the skin conditions described herein.

[0017] In one or more specific embodiments of the provided compositions and methods, a composition is provided comprising a plurality of quantum dots, each quantum dot encapsulated in an encapsulation compound that transmits a first wavelength spectrum, wherein the quantum dots are configured to absorb ambient light in the first wavelength range and emit light in a second wavelength range that is covered by the first wavelength range, wherein a first portion of the plurality of quantum dots is configured to emit light in the second wavelength range that is different from the light emitted by a second portion of the plurality of quantum dots.

[0018] In another embodiment or implementation, a composition is provided for protection against UV radiation damage, defects, or unsightly symptoms, comprising a light conversion medium that receives a broad spectrum of ambient light containing UV radiation and emits light with one or more peak wavelengths or wavelength ranges (λ1, λ2, λ3) at an intensity greater than the corresponding intensity in the received broad spectrum of ambient light.

[0019] The quantum dot compositions provided herein are configured to emit light with one or more peak wavelengths or wavelength ranges λ1, λ2, λ3, wherein the peak wavelength range is from about 200 nm to about 3000 nm, optionally in the ultraviolet band, optionally from about 200 nm to about 400 nm, optionally in the long-wave ultraviolet band, optionally from about 310 nm to about 360 nm, optionally in the visible light band, optionally from about 400 nm to about 600 nm, optionally in the infrared band, optionally from about 600 nm to about 3000 nm, optionally in the near-infrared band, optionally from about 810 nm to about 850 nm.

[0020] In one specific embodiment, the encapsulated quantum dot is configured to receive light in the range of 315–400 nm and / or 280–315 nm and to convert or emit light in the range of 600–700 nm. In a further configuration, the quantum dots are configured to absorb light in the range of 250 nm–500 nm. In one or more further configurations, some quantum dots are configured to emit light in the range of 500–700 nm. In a further configuration, one or more quantum dots in the composition emit light in the range of 630–660 nm.

[0021] As shown in FIG1, a light source 100 (e.g., natural or artificial light) emits light 110 of one or more wavelengths. These wavelengths are absorbed by the quantum dots in the composition 120.The quantum dots then emit one or more wavelengths of light (indicated by dashed lines) different from the original incident wavelength, irradiating the user's skin 130.

[0022] As shown in FIG3, in one or more configurations, the silicon-based quantum dots are configured to absorb ultraviolet light compared to a sample lacking Q dots.

[0023] In one or more further configurations, the composition includes glycerin. For example, in one or more configurations, the composition includes silicon-based quantum dots encapsulated in glycerin.

[0024] In one or more further configurations, the formulation encapsulating the quantum dots further includes an ultraviolet absorber or blocker. In a further arrangement, the composition may include one or more pigments and / or emollients.

[0025] In a further non-limiting example, the composition described herein includes a suspension or emulsion or a mixture of titanium dioxide and an organic sunscreen compound. For example, but not limited to, the composition may include one or more of the following: aminobenzoic acid, avobenzone, sinoxalate, dioxybenzone, homosalate, menthyl anthranilate, octocrylene, octyl methoxycinnamate, octyl salicylate, oxybenzone, isoamyl dimethylaminobenzoate, phenylbenzimidazole sulfonic acid, sulphone, triethanolamine salicylate, and zinc oxide.

[0026] In further non-limiting examples, the compositions described herein include one or more excipients for topical or gel matrix forms, including sodium carboxymethyl cellulose, polyacrylate, polyoxyethylene-polyoxypropylene block copolymer, polyethylene glycol, wood wax alcohol, isostearic acid, cetyl alcohol, stearyl alcohol, white petrolatum, polysorbate 60, sorbitan monostearate, glycerin, xanthan gum, water, benzyl alcohol, methylparaben, and propylparaben.

[0027] In a further non-limiting example, the compositions described herein include one or more additives selected from waxes, soaps, sorbitan esters, fatty acids, fatty acid esters, fatty acid oils, borates, cresols, chlorocresols, cellulose, methylcellulose, hydroxypropylcellulose, gum arabic, etc.

[0028] In a further embodiment, the compositions described herein provide an SPF of 15, 30, 50, or higher and are in the form of a liquid (e.g., lotion, serum), cream, or gel (e.g., ointment / gel). In a further embodiment, the formulation provides an SPF of not less than 60 SPF.

[0029] In another embodiment, the effective content of encapsulated quantum dots in the composition is in the range of 0.003–5%. In a further embodiment, the formulation includes 0.003–5% silicon quantum dots, 5–15% zinc oxide, and 10–15% titanium dioxide. The range can be expressed as mass / mass percentage (%m / m), weight / weight percentage (%w / w), weight / volume percentage (%w / v), mass / volume percentage (%m / v), or volume / volume percentage (%v / v).

[0030] In a further configuration, the composition comprises one or more collagenases, or other collagen-dissolving enzymes. For example, the composition may comprise one or more collagenases 1 (MMP-1), 2 (MMP-8), 3 (MMP-13), and 4 (MMP-18) from Xenopus laevis.

[0031] For example, one composition is provided in which the formulation further comprises 0.0003–5% encapsulated silicon quantum dots. In a further configuration, the composition is 5% encapsulated quantum dot material. In one specific configuration, the formulation further comprises 0.003–0.5% encapsulated silicon quantum dots. In one specific configuration, the formulation further comprises 0.03–0.5% encapsulated silicon quantum dots. In one specific configuration, the formulation further comprises 0.1–0.5% encapsulated silicon quantum dots. Instructions for Use, Page 3 / 6, CN 121463938 A

[0032] In a further composition, zinc oxide in the range of 5–15% is provided. In yet another further composition, titanium dioxide in the range of 10–15% is provided. In yet another further composition, at least 0.001–5% collagenase is provided.

[0033] The ranges may be expressed as %m / m, %w / w, %w / v, %m / v, or %v / v of the formulation. In a further setting, the pH of the composition is between 6 and 8.

[0034] In one or more further embodiments, the quantum dots are configured to have suppressed or reduced fluorescence. In this configuration, the quantum dots are configured to have ultraviolet absorption properties and not emit light in the wavelength range. In one configuration, this fluorescence suppression is achieved by encapsulating the quantum dots in a material that can absorb the wavelength of light emitted by the quantum dots, but is transparent to the wavelength of light that the quantum dots are configured to absorb.

[0035] In a further specific configuration, any of the foregoing compositions is provided, wherein the light conversion medium comprises a carrier medium and a light conversion element. In one or more embodiments, the composition is combined with one or more ultraviolet filters. For example, as shown in FIG2, the quantum dot formulation 220 described herein is provided to a substrate, such as glass or plastic. However, additional filtering materials (such as ultraviolet filter 210) may be combined with the substrate to provide a composite product. In this configuration, light from light source 100 first passes through filter material 210, which absorbs a portion of light at a predetermined wavelength. The light then passes through the composition described herein, further absorbing light. The quantum dots emit light of different wavelengths (shown by dashed lines) reaching the user or wearer 230.

[0036] In a further specific embodiment, any of the aforementioned compositions is provided, wherein the particulate light-converting medium is supported by a light-transmitting carrier or a support medium, optionally the support medium being transparent, translucent, or opaque.

[0037] In a further specific embodiment, any of the aforementioned compositions is provided, wherein the particulate light-converting medium is suspended in the support medium, or molecularly bonded to the support medium, thereby forming a novel hybrid material.

[0038] In a further specific embodiment, any of the aforementioned compositions is provided, wherein the support medium is a solid material, such as a plastic material, a polymer material, or an organic material, optionally the solid support medium being rigid, semi-rigid, or flexible.

[0039] In a further specific embodiment, any of the aforementioned compositions is provided, wherein the support medium is a fluid material, such as a gel, cream, or liquid.

[0040] In a further specific embodiment, any of the aforementioned compositions is provided, wherein the fluid material comprises one or more compounds, the compounds including one or more collagen-dissolving enzymes.

[0041] In a further specific embodiment, any of the aforementioned compositions is provided, wherein the fluid material can be used as an additive to existing UV-protective serums, creams, or gels.

[0042] In a further specific embodiment, any of the foregoing compositions is provided, wherein the product is a composition that can be directly applied to a subject, for example, applied to the skin, for example as a topical cream, gel, or ointment, (i) a biocompatible material, or modified to be biocompatible, or (ii) encapsulated to prevent direct contact with the subject; optionally, the encapsulated fluid-carrying medium is in the form of a gel, cream, or ointment for topical application to human skin.

[0043] In a further specific embodiment, any of the foregoing compositions is provided, wherein the skin condition, defect, or non-aesthetic symptom targeted by the composition is scar tissue, existing UV damage, wrinkles, discoloration, erythema, solar erythema, and inflammation.

[0044] In a further specific embodiment, any of the foregoing compositions is provided, wherein the product is a gel, cream, or ointment for simultaneously achieving UV protection and skin condition care.

[0045] In a further specific embodiment, any of the foregoing compositions is provided, wherein the composition can be combined or mixed with current therapeutic ingredients, formulations, or methods to enhance or differentiate from existing products.Specification page 4 / 6 7 CN 121463938 A

[0046] In a further specific embodiment, any of the foregoing compositions is provided, wherein the average diameter of the main component of the particulate matter of the light conversion medium is about 0.1 nm to about 1000 nm; optionally, about 0.1 nm to about 100 nm; optionally, about 0.1 nm to about 10 nm; optionally, about 1 nm to about 10 nm; optionally, about 10 nm to about 100 nm.

[0047] In a further specific embodiment, any of the foregoing compositions is provided, wherein the light conversion medium comprises nanocrystals or nanoparticle semiconductors.

[0048] In a further specific embodiment, any of the foregoing compositions is provided, wherein the light conversion medium comprises quantum dots or Q-dots (QDs).

[0049] In a further specific embodiment, any of the foregoing compositions is provided, wherein the light conversion medium comprises single-shell QDs, multi-shell QDs, heavy metal QDs and / or non-heavy metal QDs.

[0050] In a further specific embodiment, any of the foregoing compositions is provided, wherein the light conversion medium comprises silicon quantum dots bonded to transparent medium molecules.

[0051] In a further specific embodiment, any of the foregoing compositions is provided, wherein the light conversion medium comprises silicon quantum dots bonded to transparent medium molecules, wherein the ratio of silicon quantum dots to non-silicon quantum dots is 1:1.

[0052] In a further specific embodiment, any of the foregoing compositions is provided, wherein the light conversion medium comprises silicon quantum dots bonded to transparent medium molecules, wherein the ratio of silicon quantum dots to non-silicon quantum dots is less than 1:1.

[0053] In a further specific embodiment, any of the foregoing compositions is provided, wherein the light conversion medium comprises silicon quantum dots bonded to transparent medium molecules, wherein the ratio of silicon quantum dots to non-silicon quantum dots is greater than 1:1.

[0054] Further implementations and embodiments of the subject matter described herein may be combined with the disclosures of PCT / US21 / 18873 or U.S. Patent Publication No. 20230073172A1, both of which are incorporated herein by reference in their entirety.

[0055] Although this specification contains numerous specific implementation details, these should not be construed as limiting any embodiment or the scope of the claims, but rather as descriptions of features of particular embodiments. Certain features described in the context of different embodiments in this specification may also be implemented in combination in a single embodiment. Conversely, various features described in the context of a single embodiment may also be implemented separately in multiple embodiments, or in any suitable sub-combination. Furthermore, although features may be described as above, described in a particular combination, or even as initially claimed, in some cases one or more features may be removed from that combination, and the claimed combination may point to a sub-combination or a variation of a sub-combination.

[0056] The terminology used herein is for describing particular embodiments only and is not intended to limit the scope of the invention. The singular forms “a,” “an,” and “described” used herein should also include the plural forms unless the context clearly indicates otherwise. It is further understood that when the terms “comprising” and / or “including” are used herein, they are intended to indicate the presence of the stated features, elements, steps, operations, components, and / or parts, but do not exclude the presence or addition of one or more other features, elements, steps, operations, components, and / or combinations thereof.

[0057] It should be noted that when ordinal numbers such as “first,” “second,” “third,” etc., are used to modify claim elements in the claims, they do not individually indicate any priority, sequence, or chronological order of the claim elements, but are merely labels used to distinguish claim elements with a specific name from another element with the same name (but using an ordinal number), thus differentiating claim elements. Furthermore, the wording and terminology used herein are for descriptive purposes only and should not be considered limiting. The terms “comprising,” “including,” “having,” “containing,” “involving,” and variations thereof, as used herein, are intended to cover the items listed thereafter and their equivalents, as well as other items.

[0058] Specific embodiments have been described in this specification. Other embodiments are still within the scope of the following claims. For example, the operations listed in the claims may be performed in a different order and still achieve the desired effect. As an example, the process shown on pages 5 / 6 of the specification, CN 121463938 A, does not necessarily require that the specific order or sequence shown be performed to achieve the desired effect.

[0059] References to various publications and known registered trademarks representing different systems cited in this application are incorporated herein by reference. Reference to any of the above publications or documents does not imply an admission that they are related prior art, nor does it constitute any admission of the content or dates of such publications or documents. All references cited herein are incorporated by reference and have the same effect as if each individual publication and reference had been expressly and individually indicated as incorporated by reference.

[0060] Although the present invention has been described and illustrated in detail with reference to its preferred embodiments, those skilled in the art should understand that various modifications to its form and details can be made without departing from the spirit and scope of the invention. Therefore, the invention should not be defined solely by the foregoing description, but by the features set forth in the following claims and their equivalents. Specification 6 / 6 pages 9 CN 121463938 A Figure 1 Figure 2 Specification Drawings 1 / 2 pages 10 CN 121463938 A Figure 3 Specification Drawings 2 / 2 pages 11 CN 121463938 A

Claims

1. A composition comprising: a. A plurality of quantum dots, each quantum dot encapsulated in an encapsulation compound that transmits a first wavelength spectrum, wherein the quantum dots are configured to absorb ambient light in the first wavelength range and emit light in a second wavelength range that is covered by the first wavelength range, wherein a first portion of the plurality of quantum dots is configured to emit light in the second wavelength range that is different from the light emitted by a second portion of the plurality of quantum dots.

2. A composition for protecting against ultraviolet radiation damage, defects, or unsightly symptoms, comprising a light conversion medium that receives a broad spectrum of ambient light containing ultraviolet radiation and emits light with one or more peak wavelengths or wavelength ranges (λ1, λ2, λ3) at an intensity greater than the corresponding intensity in the received broad spectrum of ambient light.

3. The composition according to claim 2, characterized in that, The one or more peak wavelengths or wavelength ranges λ1, λ2, λ3 are from about 200 nm to about 3000 nm, optionally in the ultraviolet band, optionally from about 200 nm to about 400 nm, optionally in the long-wave ultraviolet band, optionally from about 310 nm to about 360 nm, optionally in the visible light band, optionally from about 400 nm to about 600 nm, optionally in the infrared band, optionally from about 600 nm to about 3000 nm, optionally in the near-infrared band, optionally from about 810 nm to about 850 nm.

4. The composition according to claim 2, characterized in that, The optical conversion medium includes a carrier medium and an optical conversion element.

5. The composition according to claim 4, characterized in that, The granular light conversion medium is supported by a light-transmitting carrier or a carrying medium, wherein the carrying medium may be transparent, semi-transparent or opaque.

6. The composition according to claim 5, characterized in that, The particulate light conversion medium is suspended in the carrier medium or molecularly bonded to the carrier medium, thereby forming a new hybrid material.

7. The composition according to claim 5, characterized in that, The bearing medium is a solid material, such as a plastic material, a polymer material, or an organic material. Optionally, the solid bearing medium is rigid, semi-rigid, or flexible.

8. The composition according to claim 5, characterized in that, The carrier medium is a fluid material, such as a gel, cream, or liquid.

9. The composition according to claim 8, characterized in that, The fluid material contains one or more compounds, and the compounds contain one or more collagen-dissolving enzymes.

10. The composition according to claim 9, characterized in that, The formulation comprises 0.005-5% silicon quantum dots and 5-15% zinc oxide. And titanium dioxide in the range of 10-15%. The range can be expressed as mass / mass percentage (%m / m), weight / weight percentage (%w / w), weight / volume percentage (%w / v), mass / volume percentage (%m / v), or volume / volume percentage (%v / v).

11. The composition according to claim 8, characterized in that, The product is a composition that can be directly applied to a subject, for example, applied to the skin, such as as a topical cream, gel, or ointment, (i) a biocompatible material, or modified to be biocompatible, or (ii) encapsulated to prevent direct contact with the subject, optionally the encapsulated fluid-carrying medium having the form of a gel, cream, or ointment for topical application to human skin.

12. A method for treating skin diseases, defects, or unsightly symptoms, the method comprising: An application is made of a composition comprising at least a plurality of quantum dots, each quantum dot being encapsulated in an encapsulation compound that transmits a first wavelength spectrum, wherein the quantum dots are configured to absorb ambient light in the first wavelength range and emit light in a second wavelength range that is covered by the first wavelength range, wherein a first portion of the plurality of quantum dots is configured to emit light in the second wavelength range that is different from the light emitted by a second portion of the plurality of quantum dots.

13. The method according to claim 12, characterized in that, The skin condition, defect, or unsightly symptom is one of the following: scar tissue, existing UV damage, wrinkles, discoloration, erythema, solar erythema, or inflammation.

14. The method according to claim 12, characterized in that, The composition is applied in the form of a gel, cream, or ointment.

15. The product according to claim 2, characterized in that, The product may be combined or mixed with current therapeutic ingredients, formulations or methods to enhance or differentiate it from existing products.

16. The product according to claim 2, characterized in that, The average diameter of the main component of the particulate matter in the light conversion medium is about 0.1 nm to about 1000 nm; alternatively, about 0.1 nm to about 100 nm; alternatively, about 0.1 nm to about 10 nm; alternatively, about 1 nm to about 10 nm; alternatively, about 10 nm to about 100 nm.

17. The product according to claim 2, characterized in that, The light conversion medium includes nanocrystals or nanoparticle semiconductors.

18. The product according to claim 15, characterized in that, The optical conversion medium includes quantum dots or Q dots (QDs).

19. The product according to claim 16, characterized in that, The optical conversion medium includes single-shell QDs, multi-shell QDs, heavy metal QDs, and / or non-heavy metal QDs.

20. The product according to claim 17, characterized in that, The light conversion medium comprises silicon quantum dots bonded to the molecules of the transparent medium.

Images